Cat. No. 1566
Biological ActivityHighly potent and selective nociceptin/orphanin FQ receptor (OP4) agonist peptide (pKi = 10.68; pEC50 = 9.80). Displays > 8000-fold selectivity over δ, κ, and μ opioid receptors and has relatively long lasting pronociceptive, hypotensive, negative inotropic and feeding stimulation effects in vivo.
(Modifications: Phe-4 = p-fluoro-Phe, Lys-14 = C-terminal amide)
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Bigoni et al (2002) Pharmacological characterisation of [(pX)Phe4]nociceptin(1-13)amide analogues. 1. In vitro studies. Naunyn Schmiedebergs Arch.Pharmacol. 365 442. PMID: 12070757.
Rizzi et al (2002) Pharmacological characterisation of [(pX)Phe4]nociceptin(1-13)amide analogues. 2. In vivo studies. Naunyn Schmiedebergs Arch.Pharmacol. 365 450. PMID: 12070758.
Guerrini et al (2001) Structure-activity studies of the Phe4 residue of nociceptin(1-13)-NH2: Identification of highly potent agonists of the nociceptin/orphanin FQ receptor. J.Med.Chem. 44 3956. PMID: 11689082.
If you know of a relevant reference for [(pF)Phe4]Nociceptin(1-13)NH2 please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses [(pF)Phe4]Nociceptin(1-13)NH2 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: [(pF)Phe4]Nociceptin(1-13)NH2, supplier, Potent, selective, nociceptin, receptor, agonists, Receptors, ORL1, OP4, NOP, Opioids, Tocris Bioscience, NOP Receptor Agonist products
Find multiple products by catalog number
New Products in this Area
Fluorescent opioid antagonist; fluorescent-derivative of naloxone (Cat. No. 0599)
Follow @Tocris on Twitter
Tocris is now actively tweeting. For regular updates on news, events and special offers, follow @Tocris on Twitter.